Adalimumab in psoriasis and psoriatic arthritis: A real-life 9-year experience
The patches of scaly, red, or white skin known as plaques are observed in psoriasis. In psoriatic arthritis, joint swelling and pain is seen that can further lead to it's permanent damage. Inflammation is associated with both diseases. In the regular practise, observational studies are an important complement to pivotal randomised controlled trials as their findings refer to massive and more diverse patients with common comorbidities, complex medical history, concomitant medications and longer follow-up periods.
A study has been conducted to analyse the long-term clinical outcomes of the anti-TNF-α monoclonal antibody, adalimumab, in patients with psoriasis (PsO) or psoriatic arthritis (PsA) mentioning to an Italian dermatological centre. It is a single-centre retrospective real-world investigation with an observation period of up to 9 years.
Upto 9 years, the records of 316 patients (117 with PsO and 199 with PsA) treated with adalimumab was assessed. It was seen that the safety and efficacy of adalimumab were consistent with those described in randomised controlled trials (RCTs) and other observational studies. A rapid and sustained improvement of skin lesions (evaluated as Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates) was perceived in most of the patients including, those with body mass index (BMI) >30 and with prior experience of biologic therapies (including other anti-TNFs). In elderly patients (>65 years), the safety profile of adalimumab was also confirmed.
Hence, it can be derived from this study that this real-life experience depicts the long-term treatment with adalimumab is effective and well tolerated in psoriatic patients, plus the overweight/obese, elderly and anti-TNF-experienced subjects.